240 related articles for article (PubMed ID: 22174792)
1. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.
Plissonnier ML; Fauconnet S; Bittard H; Lascombe I
PLoS One; 2011; 6(12):e28354. PubMed ID: 22174792
[TBL] [Abstract][Full Text] [Related]
2. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells.
Plissonnier ML; Fauconnet S; Bittard H; Lascombe I
Int J Cancer; 2010 Oct; 127(8):1769-84. PubMed ID: 20099277
[TBL] [Abstract][Full Text] [Related]
3. Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells.
Kang DW; Choi CH; Park JY; Kang SK; Kim YK
Neurochem Res; 2008 Mar; 33(3):551-61. PubMed ID: 17940898
[TBL] [Abstract][Full Text] [Related]
4. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
5. Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.
Plissonnier ML; Fauconnet S; Bittard H; Mougin C; Rommelaere J; Lascombe I
Oncotarget; 2017 Dec; 8(64):107744-107762. PubMed ID: 29296202
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
Lu M; Kwan T; Yu C; Chen F; Freedman B; Schafer JM; Lee EJ; Jameson JL; Jordan VC; Cryns VL
J Biol Chem; 2005 Feb; 280(8):6742-51. PubMed ID: 15569667
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
[TBL] [Abstract][Full Text] [Related]
9. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Nakata S; Yoshida T; Shiraishi T; Horinaka M; Kouhara J; Wakada M; Sakai T
Mol Cancer Ther; 2006 Jul; 5(7):1827-35. PubMed ID: 16891469
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
13. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines.
Strakova N; Ehrmann J; Dzubak P; Bouchal J; Kolar Z
J Pharmacol Exp Ther; 2004 Jun; 309(3):1239-47. PubMed ID: 14988421
[TBL] [Abstract][Full Text] [Related]
14. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
15. [The anti-diabetic drug troglitazone sensitizes colon cancer cells to TRAIL-induced apoptosis by down-regulating FLIP].
Roth W; Grund K; Wiestler OD; Schirmacher P
Verh Dtsch Ges Pathol; 2007; 91():294-301. PubMed ID: 18314627
[TBL] [Abstract][Full Text] [Related]
16. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells.
Kim SH; Yoo CI; Kim HT; Park JY; Kwon CH; Kim YK
Toxicol Appl Pharmacol; 2006 Sep; 215(2):198-207. PubMed ID: 16616945
[TBL] [Abstract][Full Text] [Related]
18. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
Siegelin MD; Reuss DE; Habel A; Herold-Mende C; von Deimling A
Mol Cancer Ther; 2008 Nov; 7(11):3566-74. PubMed ID: 19001439
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
20. Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells.
Jang JH; Sung EG; Song IH; Lee TJ; Kim JY
Anticancer Drugs; 2020 Aug; 31(7):655-662. PubMed ID: 32568826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
